Hangzhou Tigermed Consulting (03347) intends to repurchase the company's A-shares.

22:27 13/05/2026

Tage Pharmaceuticals (03347) has announced that the company plans to repurchase some of its A shares through centralized bidding trading using its own funds or self-raised funds, for the purpose of implementing A-share equity incentive plans or A-share employee stock ownership plans, as well as reducing the company's registered capital. The total amount of repurchase funds will be no less than 500 million yuan and no more than 1 billion yuan.

Hangzhou Tigermed Consulting (03347) announced that the company plans to repurchase some of its A shares through centralized competitive trading using its own funds or self-raised funds. The purpose of the repurchase is to implement an A-share equity incentive plan or an A-share employee stock ownership plan, as well as to reduce the company's registered capital. The total amount of repurchase funds will be no less than RMB 500 million and no more than RMB 1 billion.

KANGLI INT HLDG (06890): Qu Xuanhua appointed as Independent Non-Executive Director.

US Stock Market Move | NIO Inc. Sponsored ADR Class A(NIO.US) rose more than 7% in April, with total new ES8 retail sales reaching 13,020 units.

HYBRID KINETIC (01188): Wan Chuen-Long resigns as executive director and chairman of the board

KANGLI INT HLDG (06890): Qu Xuanhua appointed as Independent Non-Executive Director.

US Stock Market Move | NIO Inc. Sponsored ADR Class A(NIO.US) rose more than 7% in April, with total new ES8 retail sales reaching 13,020 units.

HYBRID KINETIC (01188): Wan Chuen-Long resigns as executive director and chairman of the board